Full Press Release Details
PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) --Krystal Biotech, Inc.(the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be availableherebeginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’swebsite.
About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visithttp://www.krystalbio.com, and follow @KrystalBiotech onLinkedInandX(formerly Twitter).